Retinal imaging company, epipole Ltd, has partnered with ophtAI (part of the Evolucare Group) and will launch their flagship product, the epiCam®, with AI analysis early in the new year. This is another significant step forward for the company in realising their mission for the eradication of preventable blindness by making high quality retinal imaging and analysis accessible to everyone.
Initially launching in the UK and Europe, the handheld epiCam powered by AI will have the ability to detect the top 5 screening targets: Diabetic Retinopathy (DR), Macular Oedema, Glaucoma, Age-related Macular Degeneration (AMD), and Drusen. epipole are demonstrating this latest development at ESCRS 2025 this coming weekend (12th to 16th September 2025), and if you’re not attending you can see a preview of how it will work here: epiCam powered by ophtAI
AI-powered retinal imaging enables faster, more accurate, and automated diagnosis, reducing dependency on specialists and therefore improving access to care for everyone and reducing healthcare costs. This is a significant step forward for epipole and ideally positions the epiCam product family as both a primary eyecare and a primary care tool. epipole CEO Sarah Jardine said “We’re committed to the eradication of preventable blindness, and partnering our cutting-edge hardware with the latest in AI for retinal imaging brings us another step closer to achieving our ambitions. This is tomorrow’s technology, today.”
